Zoetis Inc. today announced the appointment of Dr. Linda Rhodes, an accomplished scientist, academic, veterinarian and business leader in animal health, to its Board of Directors. Her appointment was effective at the close of business on Aug. 3, and she will serve on the Quality and Innovation Committee of the Board.

“I am very pleased to welcome Dr. Rhodes to the Zoetis Board of Directors,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “As an experienced veterinarian, highly respected researcher and proven executive in the animal health industry, Dr. Rhodes brings a unique combination of skills and perspectives to our Board. Her experience and insights will be valuable as Zoetis navigates the changing landscape and new technologies we need to ensure our continued growth as the world leader in animal health.”


Dr. Rhodes has extensive experience as a research scientist, academic, veterinary practitioner and business leader, spanning nearly 30 years across the animal health industry. Dr. Rhodes most recently served as the Chief Scientific Officer of Aratana Therapeutics, a publicly traded animal health company, from 2012 to 2016, and she had also served as Chief Executive Officer of Aratana from 2011 to 2012. She is a founder of AlcheraBio, LLC, a veterinary contract research organization, and held research and development positions at Merial, Merck & Company, and Sterling-Winthrop Drug Company. Dr. Rhodes also held several teaching positions and worked as a bovine veterinarian in private practice for many years. Dr. Rhodes earned her Ph.D. in Physiology from Cornell University and her V.M.D. from the University of Pennsylvania. She is currently an adjunct professor for the Graduate School of Animal Science at Rutgers University and a member of the Board of Directors of ImmuCell Corporation, a publicly traded animal health company.